This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Macular Degeneration  • Aging/ Geriatrics  • Drug Therapy  • Alert me on articles by topic

A Head-to-Head Comparison Is Needed

Arch Ophthalmol. 2007;125(4):557-558.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New England Journal of Medicine

Ranibizumab for Neovascular Age-Related Macular Degeneration 

Philip J. Rosenfeld, MD, PhD, David M. Brown, MD, Jeffrey S. Heier, MD, David S. Boyer, MD, Peter K. Kaiser, MD, Carol Y. Chung, PhD, Robert Y. Kim, MD, for the MARINA Study Group.

Background:  Ranibizumab—a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A—has been evaluated for the treatment of neovascular age-related macular degeneration.

Methods:  In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular degeneration with either minimally classic or occult (with no classic lesions) choroidal neovascularization to receive 24 monthly intravitreal injections of ranibizumab (either 0.3 mg or 0.5 mg) or sham injections. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months.

Results:  We enrolled 716 patients in the study. At 12 months, . . . [Full Text of this Article]